<DOC>
	<DOCNO>NCT00197483</DOCNO>
	<brief_summary>Dopamine closely associate prefrontal function . The hypothesis low dopaminergic activity associate negative symptom cognitive dysfunction observe patient schizophrenia heuristic value guide research area . This hypothesis lead u test whether pergolide , D1/D2 agonist , could improve negative symptom cognitive impairment prevail patient schizophrenia . This double-blind placebo control study investigate remedial effect pergolide negative symptom cognitive impairment schizophrenia .</brief_summary>
	<brief_title>Effective Adjunctive Use Pergolide Cognitive Impairment Negative Symptoms Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>Patients Were age 18–50 year , meet DSMIV criterion schizophrenia Were treat stable dose risperidone , rag 2 6mg , 8 week Had score ≥15 negative subscale item Positive Negative Syndrome Scale ( PANSS ) Had minimum period symptom stability , define 20 % change consecutive rating PANSS lease 4 week Had history medical condition drug treatment may affect cognitive performance Had history psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Pergolide</keyword>
	<keyword>Dopamine D1</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive disturbance</keyword>
	<keyword>Negative symptom</keyword>
</DOC>